Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 2/20 | 0.48 |
| ▸ | FYN | P06241 | 2/20 | 0.44 |
| ▸ | LYN | P07948 | 1/20 | 0.44 |
| ▸ | BLK | P51451 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 4/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | ABL1 | P00519 | 3/20 | 0.42 |
| ▸ | SRC | P12931 | 3/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | ABL2 | P42684 | 1/20 | 0.42 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.39 |
| ▸ | PRKDC | P78527 | 6/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16665784 | 0.83 | PIK3CD (0.55) | MAP2K4KDREGFRABL1SRC | |
| SCHEMBL11325 | 0.83 | PIK3CG (0.49) | MAP2K4KDREGFRABL1SRC | |
| SCHEMBL30387175 | 0.83 | PIK3CD (0.55) | KDREGFRABL1SRCPIK3CD | |
| SCHEMBL5065122 | 0.80 | PIK3CD (0.57) | KDREGFRABL1SRCPIK3CD | |
| SCHEMBL3782102 | 0.80 | PIK3CD (0.57) | FYNLYNBLKKDREGFR | |
| SCHEMBL15613778 | 0.80 | PIK3CD (0.42) | LYNBLKKDRABL1SRC | |
| SCHEMBL3715031 | 0.80 | SRC (0.57) | FYNLYNBLKKDREGFR | |
| SCHEMBL408618 | 0.80 | PIK3CD (0.55) | KDREGFRABL1SRCCDK1 | |
| SCHEMBL19414293 | 0.77 | ALDH1A1 (0.50) | KDREGFRABL1SRCPIK3CD | |
| SCHEMBL149528 | 0.77 | KDR (0.52) | FYNKDREGFRABL1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | MAP2K4 141/4885FYN 192/4885LYN 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.